Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$24.99

0.32 (1.30%)

14:01
10/28/18
10/28
14:01
10/28/18
14:01

Retrophin reports positive long-term data from extension of Phase 2 DUET Study

Retrophin announced new positive data from the ongoing open-label extension of the Phase 2 DUET Study of sparsentan for the treatment of focal segmental glomerulosclerosis, a rare kidney disorder that often leads to end-stage renal disease. As previously reported, the overall sparsentan treatment group demonstrated a greater than two-fold reduction in proteinuria compared to the irbesartan treatment group, after an eight-week, double-blind treatment period in the Phase 2 DUET Study. Additional results showing that patients with FSGS who remained on sparsentan for 40 weeks during the open-label extension period of DUET achieved progressive reduction in proteinuria and stable estimated glomerular filtration rate, were reported at ASN Kidney Week 2017. New findings from the open-label extension of the Phase 2 DUET Study presented at ASN Kidney Week 2018 include: Patients with FSGS who remained on sparsentan for 76 weeks during the open-label period achieved additional progressive reduction of proteinuria. In patients who received sparsentan as part of the original eight-week, double-blind treatment period, median urine protein-to-creatinine ratio was reduced from 2.8 g/g at baseline to 0.9 g/g at week 84. Patients who crossed over to sparsentan from the original irbesartan control group experienced additional and sustained reduction in proteinuria during the treatment period, with median UP/C decreasing from 2.3 g/g at crossover to 1.1 g/g at week 84. An increasing proportion of patients achieved the FSGS partial remission of proteinuria endpoint, defined as UP/C: less than or equal to1.5 g/g and greater than 40% reduction of proteinuria from baseline, with ongoing sparsentan treatment in the open-label extension. In patients who received sparsentan as part of the original eight-week, double-blind treatment period, the proportion of patients who achieved FPRE increased from 28% at week eight to 60% at week 84. The proportion of patients who crossed over to sparsentan from the original irbesartan control group and achieved FPRE increased from 9% at week eight to 50% at week 84. Treatment with sparsentan in the open-label extension was associated with a stabilization of eGFR out to week 84. The observed beneficial effects of sparsentan on proteinuria were associated with a sustained reduction in mean systolic and diastolic blood pressure. Sparsentan continued to be generally well-tolerated during the open-label extension period. Sixty-two patients continue to receive treatment with sparsentan in the ongoing open-label extension of DUET.

  • 01

    Nov

RTRX Retrophin
$24.99

0.32 (1.30%)

04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
08/17/18
ADAM
08/17/18
INITIATION
Target $36
ADAM
Buy
Retrophin initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated Retrophin with a Buy rating citing what she views as an attractive valuation given the upside potential provided by the clinical stage pipeline. She sees limited downside risk but upside catalysts with POC data for CNSA-001 in early 2019 and Phase 3 FORT data in PKAN in the second half 2019. Gilson has a $36 price target on Retrophin shares.

TODAY'S FREE FLY STORIES

WSM

Williams-Sonoma

$52.51

-1.26 (-2.34%)

07:09
01/23/19
01/23
07:09
01/23/19
07:09
Downgrade
Williams-Sonoma rating change  »

Morgan Stanley downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$128.76

-1.89 (-1.45%)

07:08
01/23/19
01/23
07:08
01/23/19
07:08
Periodicals
Johnson & Johnson pursuing acquisition of Auris Health, Bloomberg reports »

Johnson & Johnson is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 18

    Feb

CMCO

Columbus McKinnon

$33.82

-0.39 (-1.14%)

07:08
01/23/19
01/23
07:08
01/23/19
07:08
Initiation
Columbus McKinnon initiated  »

Columbus McKinnon resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

MTBC

Medical Transcription Billing

$4.36

-0.12 (-2.68%)

07:07
01/23/19
01/23
07:07
01/23/19
07:07
Recommendations
Medical Transcription Billing analyst commentary  »

Medical Transcription…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$90.50

-0.89 (-0.97%)

07:07
01/23/19
01/23
07:07
01/23/19
07:07
Earnings
Procter & Gamble reaffirms FY19 core EPS growth of 3%-8% vs. FY18 »

Consensus $4.42. "We…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 18

    Feb

  • 03

    Mar

CMCSA

Comcast

$35.16

-1.05 (-2.90%)

07:07
01/23/19
01/23
07:07
01/23/19
07:07
Hot Stocks
Comcast reports Q4 high-speed internet customer net additions 351,000 »

Total Customer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

07:07
01/23/19
01/23
07:07
01/23/19
07:07
General news
MBA Mortgage Applications Composite Index data reported »

Week of 1/18 MBA Mortgage…

GSBC

Great Southern Bancorp

$49.85

-0.7 (-1.38%)

07:05
01/23/19
01/23
07:05
01/23/19
07:05
Hot Stocks
Great Southern Bancorp declares 75c per share special cash dividend »

The board of Great…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 13

    Feb

  • 14

    Feb

SJW

SJW Corp.

$58.22

-0.16 (-0.27%)

, CTWS

Connecticut Water

$65.10

-0.62 (-0.94%)

07:05
01/23/19
01/23
07:05
01/23/19
07:05
Hot Stocks
Connecticut Water withdraws Maine Water application before SJW Corp. merger »

SJW Group (SJW) and…

SJW

SJW Corp.

$58.22

-0.16 (-0.27%)

CTWS

Connecticut Water

$65.10

-0.62 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UQM

UQM Technologies

$1.65

0.55 (50.00%)

07:04
01/23/19
01/23
07:04
01/23/19
07:04
Downgrade
UQM Technologies rating change  »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADDYY

Adidas

$0.00

(0.00%)

07:04
01/23/19
01/23
07:04
01/23/19
07:04
Periodicals
Adidas CEO says biggest concern is Brexit impact, CNBC reports »

Speaking from Davos with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$163.53

-1.58 (-0.96%)

, NOC

Northrop Grumman

$264.70

-2.84 (-1.06%)

07:04
01/23/19
01/23
07:04
01/23/19
07:04
Hot Stocks
Raytheon to maintain, cybersecure U.S. Air Force Global Hawk ground control »

Raytheon (RTN) will…

RTN

Raytheon

$163.53

-1.58 (-0.96%)

NOC

Northrop Grumman

$264.70

-2.84 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 31

    Jan

BHBK

Blue Hills Bancorp

$23.07

0.22 (0.96%)

07:04
01/23/19
01/23
07:04
01/23/19
07:04
Earnings
Blue Hills Bancorp reports Q4 EPS 28c, consensus 28c »

Reports Q4 tangible book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$35.16

-1.05 (-2.90%)

07:03
01/23/19
01/23
07:03
01/23/19
07:03
Earnings
Comcast reports Q4 adj. EPS 64c, consensus 62c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SVMK

SurveyMonkey

$12.70

-0.66 (-4.94%)

, FB

Facebook

$147.80

-2.21 (-1.47%)

07:03
01/23/19
01/23
07:03
01/23/19
07:03
Hot Stocks
SurveyMonkey hires Google and Facebook alum Joe Cummiskey »

SurveyMonkey (SVMK)…

SVMK

SurveyMonkey

$12.70

-0.66 (-4.94%)

FB

Facebook

$147.80

-2.21 (-1.47%)

GOOG

Alphabet

$1,070.72

-27.53 (-2.51%)

GOOGL

Alphabet Class A

$1,078.68

-28.24 (-2.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

PG

Procter & Gamble

$90.50

-0.89 (-0.97%)

07:02
01/23/19
01/23
07:02
01/23/19
07:02
Earnings
Procter & Gamble reports Q2 core EPS $1.25, consensus $1.21 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 18

    Feb

  • 03

    Mar

PDCE

PDC Energy

$33.52

-0.02 (-0.06%)

07:02
01/23/19
01/23
07:02
01/23/19
07:02
Initiation
PDC Energy initiated  »

PDC Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

OAS

Oasis Petroleum

$6.13

-0.66 (-9.72%)

07:01
01/23/19
01/23
07:01
01/23/19
07:01
Downgrade
Oasis Petroleum rating change  »

Oasis Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$111.23

-2.7 (-2.37%)

07:01
01/23/19
01/23
07:01
01/23/19
07:01
Hot Stocks
United Technologies sees FY19 free cash flow of $4.5B-$5.0B vs. $4.4B in FY18 »

Outlook includes $1.5B of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CPE

Callon Petroleum

$8.06

-0.21 (-2.54%)

07:00
01/23/19
01/23
07:00
01/23/19
07:00
Upgrade
Callon Petroleum rating change  »

Callon Petroleum upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

UTX

United Technologies

$111.23

-2.7 (-2.37%)

07:00
01/23/19
01/23
07:00
01/23/19
07:00
Hot Stocks
United Technologies CEO sees FY19 segment profit growth exceeding sales »

CEO Gregory Hayes says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TDY

Teledyne

$216.85

-8.2 (-3.64%)

06:58
01/23/19
01/23
06:58
01/23/19
06:58
Earnings
Breaking Earnings news story on Teledyne »

Teledyne sees FY19 GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$111.23

-2.7 (-2.37%)

06:58
01/23/19
01/23
06:58
01/23/19
06:58
Earnings
United Technologies sees FY19 EPS $7.70-$8.00, consensus $7.81 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TDY

Teledyne

$216.85

-8.2 (-3.64%)

06:57
01/23/19
01/23
06:57
01/23/19
06:57
Earnings
Breaking Earnings news story on Teledyne »

Teledyne sees Q1 GAAP EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$56.99

-0.47 (-0.82%)

06:57
01/23/19
01/23
06:57
01/23/19
06:57
Hot Stocks
Restaurant Brands reports preliminary Q4 sales for its restaurants »

Burger King comparable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.